The expanding role of co-trimoxazole in developing countries

The Lancet Infectious Diseases

Volumn 15, Issue 3, 2015, Pages 327-339

  Church, James A ^a   Fitzgerald, Felicity ^b   Walker, A Sarah ^c   Gibb, Diana M ^c   Prendergast, Andrew J ^a,c,d  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c MRC CLINICAL TRIALS UNIT   (United Kingdom)

^d Zvitambo Institute for Maternal and Child Health Research   (Zimbabwe)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; DEVELOPING COUNTRY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG USE; FETUS GROWTH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTESTINE FLORA; MORBIDITY; MORTALITY; NONHUMAN; PRACTICE GUIDELINE; PREGNANCY OUTCOME; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SUSCEPTIBLE POPULATION; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CHEMOPROPHYLAXIS; CLINICAL TRIAL (TOPIC); COMPLICATION; PROCEDURES; TREATMENT OUTCOME;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-INFECTIVE AGENTS; ANTIMALARIALS; CHEMOPREVENTION; CLINICAL TRIALS AS TOPIC; DEVELOPING COUNTRIES; HIV INFECTIONS; HUMANS; TREATMENT OUTCOME; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 84923289950     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(14)71011-4     Document Type: Review

References (151)

1. Septrin and bactrim. A combination of trimethoprim and sulphamethoxazole. Drug Ther Bull 1969, 7:13-15. Anon.
2. Wolff LJ, Baehner RL Delayed development of pneumocystis pneumonia following administration of short-term high-dose trimethoprim-sulfamethoxazole. Am J Dis Child 1978, 132:525-526.
3. Hughes WT Trimethoprim-sulfamethoxazole therapy for Pneumocystis carinii pneumonitis in children. Rev Infect Dis 1982, 4:602-607.
4. Ruskin J, LaRiviere M Low-dose co-trimoxazole for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus disease. Lancet 1991, 337:468-471.
5. Emmanouilides CE, Lianou PE, Bassaris HP, Papavassiliou JT Trimethoprim, sulphamethoxazole, bacterial adhesion and polymorphonuclear leucocyte function. J Antimicrob Chemother 1990, 26:803-812.
6. Chintu C, Bhat GJ, Walker AS, et al. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet 2004, 364:1865-1871.
7. Lindemulder S, Albano E Successful intermittent prophylaxis with trimethoprim/sulfamethoxazole 2 days per week for Pneumocystis carinii (jiroveci) pneumonia in pediatric oncology patients. Pediatrics 2007, 120:e47-e51.
8. Bwakura-Dangarembizi M, Kendall L, Bakeera-Kitaka S, et al. A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa. N Engl J Med 2014, 370:41-53.
9. Masters PA, O'Bryan TA, Zurlo J, Miller DQ, Joshi N Trimethoprim-sulfamethoxazole revisited. Arch Intern Med 2003, 163:402-410.
10. Brumfitt W, Hamilton-Miller JM Limitations of and indications for the use of co-trimoxazole. J Chemother 1994, 6:3-11.
11. Goldberg E, Bishara J Contemporary unconventional clinical use of co-trimoxazole. Clin Microbiol Infect 2012, 18:8-17.
12. Mermin J, Ekwaru JP, Liechty CA, et al. Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study. Lancet 2006, 367:1256-1261.
13. Cavalcante Rde S, Sylvestre TF, Levorato AD, de Carvalho LR, Mendes RP Comparison between itraconazole and cotrimoxazole in the treatment of paracoccidiodomycosis. PLoS Negl Trop Dis 2014, 8:e2793.
14. Rigaud M, Pollack H, Leibovitz E, et al. Efficacy of primary chemoprophylaxis against Pneumocystis carinii pneumonia during the first year of life in infants infected with human immunodeficiency virus type 1. J Pediatr 1994, 125:476-480.
15. Stansell JD, Osmond DH, Charlebois E, et al. Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 1997, 155:60-66.
16. Anglaret X, Chene G, Attia A, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d'Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet 1999, 353:1463-1468.
17. Mermin J, Lule J, Ekwaru JP, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004, 364:1428-1434.
18. Wiktor SZ, Sassan-Morokro M, Grant AD, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial. Lancet 1999, 353:1469-1475.
19. Badri M, Ehrlich R, Wood R, Maartens G Initiating co-trimoxazole prophylaxis in HIV-infected patients in Africa: an evaluation of the provisional WHO/UNAIDS recommendations. AIDS 2001, 15:1143-1148.
20. Mulenga V, Ford D, Walker AS, et al. Effect of cotrimoxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children. AIDS 2007, 21:77-84.
21. Abouya YL, Beaumel A, Lucas S, Dago-Akribi A, Coulibaly G, N'Dhatz M, et al. Pneumocystis carinii pneumonia. An uncommon cause of death in African patients with acquired immunodeficiency syndrome. Am Rev Respir Dis 1992, 145:617-620.
22. Kamanfu G, Mlika-Cabanne N, Girard PM, et al. Pulmonary complications of human immunodeficiency virus infection in Bujumbura, Burundi. Am Rev Respir Dis 1993, 147:658-663.
23. Batungwanayo J, Taelman H, Lucas S, et al. Pulmonary disease associated with the human immunodeficiency virus in Kigali, Rwanda. A fiberoptic bronchoscopic study of 111 cases of undetermined etiology. Am J Respir Crit Care Med 1994, 149:1591-1596.
24. Atzori C, Bruno A, Chichino G, Gatti S, Scaglia M Pneumocystis carinii pneumonia and tuberculosis in Tanzanian patients infected with HIV. Trans R Soc Trop Med Hyg 1993, 87:55-56.
25. Lucas SB, Hounnou A, Peacock C, et al. The mortality and pathology of HIV infection in a west African city. AIDS 1993, 7:1569-1579.
26. Chintu C, Mudenda V, Lucas S, et al. Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study. Lancet 2002, 360:985-990.
27. Zar HJ, Dechaboon A, Hanslo D, Apolles P, Magnus KG, Hussey G Pneumocystis carinii pneumonia in South African children infected with human immunodeficiency virus. Pediatr Infect Dis J 2000, 19:603-607.
28. Ruffini DD, Madhi SA The high burden of Pneumocystis carinii pneumonia in African HIV-1-infected children hospitalized for severe pneumonia. AIDS 2002, 16:105-112.
29. Yazdanpanah Y, Losina E, Anglaret X, Goldie SJ, et al. Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Cote d'Ivoire: a trial-based analysis. AIDS 2005, 19:1299-1308.
30. Ryan M, Griffin S, Chitah B, et al. The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia. AIDS 2008, 22:749-757.
31. Hudson CP, Roach T Co-trimoxazole in HIV-1 infection. Lancet 1999, 354:333.
32. Ledergerber B, Mocroft A, Reiss P, et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. N Engl J Med 2001, 344:168-174.
33. Mussini C, Pezzotti P, Govoni A, et al. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study. J Infect Dis 2000, 181:1635-1642.
34. Urschel S, Ramos J, Mellado M, et al. Withdrawal of Pneumocystis jirovecii prophylaxis in HIV-infected children under highly active antiretroviral therapy. AIDS 2005, 19:2103-2108.
35. Welch S, Sharland M, et al. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med 2009, 10:591-613. PENTA Steering Committee.
36. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. US Department of Health and Human Services Panel on opportunistic infections in HIV-exposed and HIV-infected Children, (accessed July 8, 2014). http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf.
37. UNAIDS report on the global AIDS epidemic 2013 UNAIDS, (accessed May 25, 2014). http://www.unaids.org/en/resources/campaigns/globalreport2013/globalreport/.
38. Suthar AB, Granich R, Mermin J, Van Rie A Effect of cotrimoxazole on mortality in HIV-infected adults on antiretroviral therapy: a systematic review and meta-analysis. Bull World Health Organ 2012, 90:128C-138C.
39. Abimbola TO, Marston BJ The cost-effectiveness of cotrimoxazole in people with advanced HIV infection initiating antiretroviral therapy in sub-Saharan Africa. J Acquir Immune Defic Syndr 2012, 60:e8-e14.
40. Walker AS, Ford D, Gilks CF, et al. Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet 2010, 375:1278-1286.
41. Watera C, Todd J, Muwonge R, et al. Feasibility and effectiveness of cotrimoxazole prophylaxis for HIV-1-infected adults attending an HIV/AIDS clinic in Uganda. J Acquir Immune Defic Syndr 2006, 42:373-378.
42. Campbell JD, Moore D, Degerman R, et al. HIV-infected ugandan adults taking antiretroviral therapy with CD4 counts >200 cells/muL who discontinue cotrimoxazole prophylaxis have increased risk of malaria and diarrhea. Clin Infect Dis 2012, 54:1204-1211.
43. Polyak CS, Yuhas K, Benson S, Khaemba M, Walson J, Richardson B, et al. Cotrimoxazole prophylaxis discontinuation among ART-treated adults: a randomised non-inferiority trial. 21st Conference on Retroviruses and Opportunistic Infections; Boston, MA, USA; March 3-6, 2014. Abstract 98.
44. Nachman S, Gona P, Dankner W, et al. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis. Pediatrics 2005, 115:e488-e494.
45. Moh R, Danel C, Sorho S, et al. Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in CÔte d'Ivoire. Antivir Ther 2005, 10:615-624.
46. Reid DW, Caille G, Kaufmann NR Maternal and transplacental kinetics of trimethoprim and sulfamethoxazole, separately and in combination. Can Med Assoc J 1975, 112:67-72.
47. Wilkinson PJ, Reeves DS Tissue penetration of trimethoprim and sulphonamides. J Antimicrob Chemother 1979, 5:159-168.
48. WHO 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection (accessed May 25, 2014). http://www.who.int/hiv/pub/guidelines/arv2013/arvs2013upplement_march2014/en/.
49. Walter J, Mwiya M, Scott N, et al. Reduction in preterm delivery and neonatal mortality after the introduction of antenatal cotrimoxazole prophylaxis among HIV-infected women with low CD4 cell counts. J Infect Dis 2006, 194:1510-1518.
50. Nunn AJ, Mwaba PB, Chintu C, et al. Randomised, placebo-controlled trial to evaluate co-trimoxazole to reduce mortality and morbidity in HIV-infected post-natal women in Zambia (TOPAZ). Trop Med Int Health 2011, 16:518-526.
51. Updated WHO policy recommendation: intermittent preventive treatment of malaria in pregnancy using sulfadoxine-pyrimethamine (IPTp-SP) WHO, (accessed on May 25, 2014). http://www.who.int/malaria/publications/atoz/who_iptp_sp_policy_recommendation/en/.
52. ter Kuile FO, Parise ME, Verhoeff FH, et al. The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-saharan Africa. Am J Trop Med Hyg 2004, 71:41-54.
53. Manyando C, Njunju EM, D'Alessandro U, Van Geertruyden JP Safety and efficacy of co-trimoxazole for treatment and prevention of Plasmodium falciparum malaria: a systematic review. PLoS One 2013, 8:e56916.
54. Klement E, Pitche P, Kendjo E, et al. Effectiveness of co-trimoxazole to prevent Plasmodium falciparum malaria in HIV-positive pregnant women in sub-Saharan Africa: an open-label, randomized controlled trial. Clin Infect Dis 2014, 58:651-659.
55. Manyando C, Njunju EM, Mwakazanga D, et al. Safety of daily co-trimoxazole in pregnancy in an area of changing malaria epidemiology: a phase 3b randomized controlled clinical trial. PloS One 2014, 9:e96017.
56. Denoeud-Ndam L, Zannou DM, Fourcade C, et al. Cotrimoxazole prophylaxis versus mefloquine intermittent preventive treatment to prevent malaria in HIV-infected pregnant women: two randomized controlled trials. J Acquir Immune Defic Syndr 2014, 65:198-206.
57. Dow A, Kayira D, Hudgens MG, et al. The effect of cotrimoxazole prophylactic treatment on malaria, birth outcomes, and postpartum CD4 count in HIV-infected women. Infect Dis Obstet Gynecol 2013, 2013:340702.
58. Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults 2006, WHO, WHO, Geneva, (accessed July 7, 2014). http://www.who.int/hiv/pub/guidelines/ctx/en/.
59. Provisional WHO/UNAIDS ecommendations on the use of cotrimoxazole prophylaxis in adults and children living with HIV/AIDS in Africa. Afr Health Sci 2001, 1:30-31. World Health Organization/UNAIDS.
60. Barker PM, Mphatswe W, Rollins N Antiretroviral drugs in the cupboard are not enough: the impact of health systems' performance on mother-to-child transmission of HIV. J Acquir Immune Defic Syndr 2011, 56:e45-e48.
61. Marinda E, Humphrey JH, Iliff PJ, et al. Child mortality according to maternal and infant HIV status in Zimbabwe. Pediatr Infect Dis J 2007, 26:519-526.
62. McNally LM, Jeena PM, Gajee K, et al. Effect of age, polymicrobial disease, and maternal HIV status on treatment response and cause of severe pneumonia in South African children: a prospective descriptive study. Lancet 2007, 369:1440-1451.
63. Heresi GP, Caceres E, Atkins JT, Reuben J, Doyle M Pneumocystis carinii pneumonia in infants who were exposed to human immunodeficiency virus but were not infected: an exception to the AIDS surveillance case definition. Clin Infect Dis 1997, 25:739-740.
64. Sandison TG, Homsy J, Arinaitwe E, et al. Protective efficacy of co-trimoxazole prophylaxis against malaria in HIV exposed children in rural Uganda: a randomised clinical trial. BMJ 2011, 342:d1617.
65. Dow A, Kayira D, Hudgens M, et al. Effects of cotrimoxazole prophylactic treatment on adverse health outcomes among HIV-exposed, uninfected infants. Pediatr Infect Dis J 2012, 31:842-847.
66. Coutsoudis A, Pillay K, Spooner E, Coovadia HM, Pembrey L, Newell ML Routinely available cotrimoxazole prophylaxis and occurrence of respiratory and diarrhoeal morbidity in infants born to HIV-infected mothers in South Africa. S Afr Med J 2005, 95:339-345.
67. Rieder MJ, King SM, Read S Adverse reactions to trimethoprim-sulfamethoxazole among children with human immunodeficiency virus infection. Pediatr Infect Dis J 1997, 16:1028-1031.
68. Coutsoudis A, Coovadia HM, Kindra G Time for new recommendations on cotrimoxazole prophylaxis for HIV-exposed infants in developing countries?. Bull World Health Organ 2010, 88:949-950.
69. Dryden-Peterson S, Jayeoba O, Hughes MD, et al. Cotrimoxazole prophylaxis and risk of severe anemia or severe neutropenia in HAART-exposed, HIV-uninfected infants. PLoS One 2013, 8:e74171.
70. Kourtis AP, Ibegbu CC, Wiener J, et al. Role of intestinal mucosal integrity in HIV transmission to infants through breast-feeding: the BAN study. J Infect Dis 2013, 208:653-661.
71. Gill CJ, Mwanakasale V, Fox MP, et al. Effect of presumptive co-trimoxazole prophylaxis on pneumococcal colonization rates, seroepidemiology and antibiotic resistance in Zambian infants: a longitudinal cohort study. Bull World Health Organ 2008, 86:929-938.
72. Mwenya DM, Charalambous BM, Phillips PP, et al. Impact of cotrimoxazole on carriage and antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae in HIV-infected children in Zambia. Antimicrob Agents Chemother 2010, 54:3756-3762.
73. Kohler PK, Chung MH, McGrath CJ, Benki-Nugent SF, Thiga JW, John-Stewart GC Implementation of free cotrimoxazole prophylaxis improves clinic retention among antiretroviral therapy-ineligible clients in Kenya. AIDS 2011, 25:1657-1661.
74. Lim PL, Zhou J, Ditangco RA, et al. Failure to prescribe pneumocystis prophylaxis is associated with increased mortality, even in the cART era: results from the Treat Asia HIV observational database. J Int AIDS Soc 2012, 15:1.
75. Global HIV/AIDS response: epidemic update and health sector progress towards universal access 2011, WHO, WHO, UNICEF, UNAIDS, (accessed July 7, 2014). http://www.who.int/hiv/pub/progress_report2011/en/.
76. Hutchinson E, Droti B, Gibb D, et al. Translating evidence into policy in low-income countries: lessons from co-trimoxazole preventive therapy. Bull World Health Organ 2011, 89:312-316.
77. Anglaret X, Messou E, Ouassa T, et al. Pattern of bacterial diseases in a cohort of HIV-1 infected adults receiving cotrimoxazole prophylaxis in Abidjan, Cote d'Ivoire. AIDS 2003, 17:575-584.
78. Ashley EA, Lubell Y, White NJ, Turner P Antimicrobial susceptibility of bacterial isolates from community acquired infections in Sub-Saharan Africa and Asian low and middle income countries. Trop Med Int Health 2011, 16:1167-1179.
79. Chiller TM, Polyak CS, Brooks JT, et al. Daily trimethoprim-sulfamethoxazole prophylaxis rapidly induces corresponding resistance among intestinal Escherichia coli of HIV-infected adults in Kenya. J Int Assoc Physicians AIDS Care (Chic) 2009, 8:165-169.
80. Hamel MJ, Greene C, Chiller T, et al. Does cotrimoxazole prophylaxis for the prevention of HIV-associated opportunistic infections select for resistant pathogens in Kenyan adults?. Am J Trop Med Hyg 2008, 79:320-330.
81. Madhi SA, Petersen K, Madhi A, Khoosal M, Klugman KP Increased disease burden and antibiotic resistance of bacteria causing severe community-acquired lower respiratory tract infections in human immunodeficiency virus type 1-infected children. Clin Infect Dis 2000, 31:170-176.
82. Reddy EA, Shaw AV, Crump JA Community-acquired bloodstream infections in Africa: a systematic review and meta-analysis. Lancet Infect Dis 2010, 10:417-432.
83. Mermin J, Lule J, Ekwaru JP, et al. Cotrimoxazole prophylaxis by HIV-infected persons in Uganda reduces morbidity and mortality among HIV-uninfected family members. AIDS 2005, 19:1035-1042.
84. Phetsouvanh R, Phongmany S, Soukaloun D, et al. Causes of community-acquired bacteremia and patterns of antimicrobial resistance in Vientiane, Laos. Am J Trop Med Hyg 2006, 75:978-985.
85. Cotton MF, Wasserman E, Smit J, Whitelaw A, Zar HJ High incidence of antimicrobial resistant organisms including extended spectrum beta-lactamase producing Enterobacteriaceae and methicillin-resistant Staphylococcus aureus in nasopharyngeal and blood isolates of HIV-infected children from Cape Town, South Africa. BMC Infect Dis 2008, 8:40.
86. Scott JA, Mwarumba S, Ngetsa C, et al. Progressive increase in antimicrobial resistance among invasive isolates of Haemophilus influenzae obtained from children admitted to a hospital in Kilifi, Kenya, from 1994 to 2002. Antimicrob Agents Chemother 2005, 49:3021-3024.
87. Watera C, Todd J, Muwonge R, et al. Feasibility and effectiveness of cotrimoxazole prophylaxis for HIV-1-infected adults attending an HIV/AIDS clinic in Uganda. J Acquir Immune Defic Syndr 2006, 42:373-378.
88. Everett DB, Mukaka M, Denis B, et al. Ten years of surveillance for invasive Streptococcus pneumoniae during the era of antiretroviral scale-up and cotrimoxazole prophylaxis in Malawi. PLoS One 2011, 6:e17765.
89. Kariuki S, Revathi G, Kariuki N, Kiiru J, Mwituria J, Hart CA Characterisation of community acquired non-typhoidal Salmonella from bacteraemia and diarrhoeal infections in children admitted to hospital in Nairobi, Kenya. BMC Microbiol 2006, 6:101.
90. van Oosterhout JJ, Laufer MK, Graham SM, et al. A community-based study of the incidence of trimethoprim-sulfamethoxazole-preventable infections in Malawian adults living with HIV. J Acquir Immune Defic Syndr 2005, 39:626-631.
91. Kamya MR, Gasasira AF, Achan J, et al. Effects of trimethoprim-sulfamethoxazole and insecticide-treated bednets on malaria among HIV-infected Ugandan children. AIDS 2007, 21:2059-2066.
92. Malamba SS, Mermin J, Reingold A, et al. Effect of cotrimoxazole prophylaxis taken by human immunodeficiency virus (HIV)-infected persons on the selection of sulfadoxine-pyrimethamine-resistant malaria parasites among HIV-uninfected household members. Am J Trop Med Hyg 2006, 75:375-380.
93. Thera MA, Sehdev PS, Coulibaly D, et al. Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and disease. J Infect Dis 2005, 192:1823-1829.
94. Musiime V, Cook A, Bakeera-Kitaka S, et al. Bacteremia, causative agents and antimicrobial susceptibility among HIV-1-infected children on antiretroviral therapy in Uganda and Zimbabwe. Pediatr Infect Dis J 2013, 32:856-862.
95. Pemba L, Charalambous S, von Gottberg A, et al. Impact of cotrimoxazole on non-susceptibility to antibiotics in Streptococcus pneumoniae carriage isolates among HIV-infected mineworkers in South Africa. J Infect 2008, 56:171-178.
96. Soeters HM, von Gottberg A, Cohen C, Quan V, Klugman KP Trimethoprim-sulfamethoxazole prophylaxis and antibiotic nonsusceptibility in invasive pneumococcal disease. Antimicrobial Agents Chemother 2012, 56:1602-1605.
97. Zar HJ, Hanslo D, Hussey G The impact of HIV infection and trimethoprim-sulphamethoxazole prophylaxis on bacterial isolates from children with community-acquired pneumonia in South Africa. J Trop Pediatr 2003, 49:78-83.
98. Mwansa J, Mutela K, Zulu I, Amadi B, Kelly P Antimicrobial sensitivity in enterobacteria from AIDS patients, Zambia. Emerg Infect Dis 2002, 8:92-93.
99. Jones KDJ, Berkley JA Severe acute malnutrition and infection; CMAM FORUM technical brief (accessed May 25, 2014). http://www.cmamforum.org/resource/936.
100. Kalliomaki JL A therapeutic trial with a combination of trimethoprim-sulphamethoxazole in rheumatoid arthritis. Curr Ther Res Clin Exp 1972, 14:22-25.
101. Valeriano-Marcet J, Spiera H Treatment of Wegener's granulomatosis with sulfamethoxazole-trimethoprim. Arch Intern Med 1991, 151:1649-1652.
102. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996, 335:16-20.
103. Tadema H, Heeringa P, Kallenberg CG Bacterial infections in Wegener's granulomatosis: mechanisms potentially involved in autoimmune pathogenesis. Curr Opinion Rheumatol 2011, 23:366-371.
104. Rozin A, Schapira D, Braun-Moscovici Y, Nahir AM Cotrimoxazole treatment for rheumatoid arthritis. Semin Arthritis Rheum 2001, 31:133-141.
105. Ash G, Baker R, Rajapakse C, Swinson DR Study of sulphamethoxazole in rheumatoid arthritis. Br J Rheumatol 1986, 25:285-287.
106. Ghilchik MW, Morris AS, Reeves DS Immunosuppressive powers of the antibacterial agent trimethoprim. Nature 1970, 227:393-394.
107. Gaylarde PM, Sarkany I Suppression of thymidine uptake of human lymphocytes by co-trimoxazole. BMJ 1972, 3:144-146.
108. Nguyen BT, Stadtsbaeder S In vitro activity of cotrimoxazole on the intracellular multiplication of Toxoplasma gondii. Pathol Eur 1975, 10:307-315.
109. Nesthus I, Haneberg B, Glette J, Solberg CO The influence of antimicrobial agents on macrophage-associated Staphylococcus aureus. Acta Pathol Microbiol Immunol ScandB 1985, 93:189-194.
110. Vilde JL, Dournon E, Rajagopalan P Inhibition of Legionella pneumophila multiplication within human macrophages by antimicrobial agents. Antimicrob Agents Chemother 1986, 30:743-748.
111. Luppi F, Covi M, Velluti G, Spagnolo P, Fabbri LM, Richeldi L Co-trimoxazole effect on human alveolar macrophages of AIDS patients. J Biol Regul Homeost Agents 2011, 25:461-464.
112. Anderson R, Grabow G, Oosthuizen R, Theron A, Van Rensburg AJ Effects of sulfamethoxazole and trimethoprim on human neutrophil and lymphocyte functions in vitro: in vivo effects of co-trimoxazole. Antimicrob Agents Chemother 1980, 17:322-326.
113. Wolfish NM, Wassef N, Gonzalez H, Acharya C Immunologic parameters of children with urinary tract infection: effects of trimethoprim-sulfamethoxazole. Can Med Assoc J 1975, 112:76-79.
114. Dubar V, Lopez I, Gosset P, Aerts C, Voisin C, Wallaert B The penetration of co-trimoxazole into alveolar macrophages and its effect on inflammatory and immunoregulatory functions. J Antimicrob Chemother 1990, 26:791-802.
115. Ballieux BE, van der Burg SH, Hagen EC, van der Woude FJ, Melief CJ, Daha MR Cell-mediated autoimmunity in patients with Wegener's granulomatosis (WG). Clin Exp Immunol 1995, 100:186-193.
116. Ambrose NS, Allan RN, Keighley MR, et al. Antibiotic therapy for treatment in relapse of intestinal Crohn's disease. A prospective randomized study. Dis Colon Rectum 1985, 28:81-85.
117. Gessler C Favorable effect of trimethoprim-sulfonamide (Eusaprim) in a case of hemorrhagic rectocolitis. Acta clinica Belgica 1973, 28:17-19.
118. Humphrey JH Child undernutrition, tropical enteropathy, toilets, and handwashing. Lancet 2009, 374:1032-1035.
119. Prendergast AJ, Rukobo S, Chasekwa B, et al. Stunting is characterized by chronic inflammation in Zimbabwean infants. PloS ONE 2014, 9:e86928.
120. Prendergast A, Walker AS, Mulenga V, Chintu C, Gibb DM Improved growth and anemia in HIV-infected African children taking cotrimoxazole prophylaxis. Clin Infect Dis 2011, 52:953-956.
121. Prendergast AJ, Bwakura-Dangarembizi M, Musiime V, et al. Lower inflammatory biomarkers in children randomized to prolonged cotrimoxazole prophylaxis. 21st Conference on Retroviruses and Opportunistic Infections; Boston, MA, USA; March 3-6, 2014. Poster 914.
122. Tahan S, Melli LC, Mello CS, Rodrigues MS, Bezerra H, de Morais MB Effectiveness of trimethoprim-sulfamethoxazole plus metronidazole in the treatment of small intestinal bacterial overgrowth in children living in a slum. J Pediatr Gastroenterol Nutr 2013, 57:316-318.
123. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006, 12:1365-1371.
124. Gough EK, Moodie EE, Prendergast AJ, et al. The impact of antibiotics on growth in children in low and middle income countries: systematic review and meta-analysis of randomised controlled trials. BMJ 2014, 348:g2267.
125. Castetbon K, Anglaret X, Attia A, et al. Effect of early chemoprophylaxis with co-trimoxazole on nutritional status evolution in HIV-1-infected adults in Abidjan, Cote d'Ivoire. AIDS 2001, 15:869-876.
126. Glennie SJ, Williams NA, Heyderman RS Mucosal immunity in resource-limited setting: is the battle ground different?. Trends Microbiol 2010, 18:487-493.
127. Prendergast A, Kelly P Enteropathies in the developing world: neglected effects on global health. Am J Trop Med Hyg 2012, 86:756-763.
128. Alam NH, Bardhan PK, Haider R, Mahalanabis D Trimethoprim-sulphamethoxazole in the treatment of persistent diarrhoea: a double blind placebo controlled clinical trial. Arch Dis Child 1995, 72:483-486.
129. Berkley JA, Lowe BS, Mwangi I, Williams T, Bauni E, Mwarumba S, et al. Bacteremia among children admitted to a rural hospital in Kenya. N Engl J Med 2005, 352:39-47.
130. Abrha A, Abdissa A, Beyene G, Getahun G, Girma T Bacteraemia among severely malnourished children in Jimma University Hospital, Ethiopia. Ethiop J Health Sci 2011, 21:175-182.
131. Bachou H, Tylleskar T, Kaddu-Mulindwa DH, Tumwine JK Bacteraemia among severely malnourished children infected and uninfected with the human immunodeficiency virus-1 in Kampala, Uganda. BMC Infect Dis 2006, 6:160.
132. Page AL, de Rekeneire N, Sayadi S, et al. Infections in children admitted with complicated severe acute malnutrition in Niger. PLoS One 2013, 8:e68699.
133. Trehan I, Maleta KM, Manary MJ Antibiotics for uncomplicated severe malnutrition. N Engl J Med 2013, 368:2436-2437.
134. Smith MI, Yatsunenko T, Manary MJ, et al. Gut microbiomes of Malawian twin pairs discordant for kwashiorkor. Science 2013, 339:548-554.
135. Simoncini GM, Khanlou H TMP/SMX is still the preferred empiric antibiotic for methicillin-resistant Staphylococcus aureus skin and soft tissue infection in the HIV population. J Acquir Immune Defic Syndr 2012, 59:e78.
136. Chetchotisakd P, Chierakul W, Chaowagul W, et al. Trimethoprim-sulfamethoxazole versus trimethoprim-sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): a multicentre, double-blind, non-inferiority, randomised controlled trial. Lancet 2014, 383:807-814.
137. Alavi SM, Alavi L Treatment of brucellosis: a systematic review of studies in recent twenty years. Caspian J Intern Med 2013, 4:636-641.
138. Wang YL, Scipione MR, Dubrovskaya Y, Papadopoulos J Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. Antimicrob Agents Chemother 2014, 58:176-182.
139. Mihaila RG, Blaga L Burkholderia cepacia septicemia in a patient with acute myeloid leukemia in postchemotherapy bone marrow aplasia. Pak J Med Sci 2013, 29:1275-1277.
140. Angelakis E, Million M, D'Amato F, et al. Q fever and pregnancy: disease, prevention, and strain specificity. Eur J Clin Microbiol Infect Dis 2013, 32:361-368.
141. Boden K, Brueckmann A, Wagner-Wiening C, et al. Maternofetal consequences of Coxiella burnetii infection in pregnancy: a case series of two outbreaks. BMC Infect Dis 2012, 12:359.
142. Forgacs P, Wengenack NL, Hall L, Zimmerman SK, Silverman ML, Roberts GD Tuberculosis and trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother 2009, 53:4789-4793.
143. Huang TS, Kunin CM, Yan BS, Chen YS, Lee SS, Syu W Susceptibility of Mycobacterium tuberculosis to sulfamethoxazole, trimethoprim and their combination over a 12 year period in Taiwan. J Antimicrob Chemother 2012, 67:633-637.
144. Hasse B, Walker AS, Fehr J, et al. Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study. Antimicrob Agents Chemother 2014, 58:2363-2368.
145. Hoffmann CJ, Chaisson RE, Martinson NA Cotrimoxazole prophylaxis and tuberculosis risk among people living with HIV. PLoS ONE 2014, 9:e83750.
146. Alsaad N, van der Laan T, van Altena R, et al. Trimethoprim/sulfamethoxazole susceptibility of Mycobacterium tuberculosis. Int J Antimicrob Agents 2013, 42:472-474.
147. Sharma NK, Garg R, Baliga S, Bhat KG Nosocomial infections and drug susceptibility patterns in methicillin sensitive and methicillin resistant Staphylococcus aureus. J Clin Diagn Res 2013, 7:2178-2180.
148. Campbell ML, Marchaim D, Pogue JM, et al. Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 mug/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents. Ann Pharmacother 2012, 46:1587-1597.
149. Forcade NA, Parchman ML, Jorgensen JH, et al. Prevalence, severity, and treatment of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) skin and soft tissue infections in 10 medical clinics in Texas: a South Texas Ambulatory Research Network (STARNet) study. J Am Board Fam Med 2011, 24:543-550.
150. Pulido Perez A, Baniandres Rodriguez O, Ceballos Rodriguez MC, Mendoza Cembranos MD, Campos Dominguez M, Suarez Fernandez R Skin infections caused by community-acquired methicillin-resistant Staphylococcus aureus: clinical and microbiological characteristics of 11 cases. Actas Dermosifiliogr 2014, 105:150-158.
151. Bhutta ZA Antibiotics to promote growth in children?. BMJ 2014, 348:g2624.